Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-21T17:39:23.409Z Has data issue: false hasContentIssue false

Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Aan Het Rot, M, Zarate, CA Jr, Charney, DS, Mathew, SJ (2012). Ketamine for depression: where do we go from here? Biol Psychiatry, 72(7), 537547. doi:10.1016/j.biopsych.2012.05.003.CrossRefGoogle Scholar
Aberg-Wistedt, A, Agren, H, Ekselius, L, Bengtsson, F, Akerblad, AC (2000). Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol, 20, 645652.Google Scholar
Adli, M, Baethge, C, Heinz, A, Langlitz, N, Bauer, M (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci, 255, 387400.CrossRefGoogle ScholarPubMed
Akerblad, AC, Bengtsson, F, von Knorring, L, Ekselius, L (2006). Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol, 21, 117124.Google Scholar
Alvarez, E, Perez, V, Artigas, F (2014). Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat, 10, 12971307.Google Scholar
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.Google Scholar
Anderson, IM (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord, 58, 1936.CrossRefGoogle ScholarPubMed
Anderson, IM (2001). Meta-analytical studies on new antidepressants. Br Med Bull, 57, 161178.Google Scholar
Anderson, IM (2003). Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat, 9, 1120.CrossRefGoogle Scholar
Anglin, R, Yuan, Y, Moayyedi, P, et al. (2014). Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol, 109(6), 811819. doi:10.1038/ajg.2014.82.CrossRefGoogle ScholarPubMed
Angst, J, Scheidegger, P, Stabl, M (1993). Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale. Clin Neuropharmacol, 16(Suppl 2), S55S62.Google ScholarPubMed
Angst, J, Gamma, A, Bowden, CL, et al. (2012). Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci, 262(1), 311. doi:10.1007/s00406-011-0228-0.CrossRefGoogle Scholar
Appelberg, BG, Syvalahti, EK, Koskinen, TE, et al. (2001). Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry, 62, 448452.CrossRefGoogle ScholarPubMed
Aronson, R, Offman, HJ, Joffe, RT, Naylor, CD (1996). Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry, 53, 842848.Google Scholar
Bair, MJ, Robinson, RL, Eckert, GJ, et al. (2004). Impact of pain on depression treatment response in primary care. Psychosom Med, 66, 1722.CrossRefGoogle ScholarPubMed
Baldessarini, RJ, Tondo, L, Ghiana, C, Lepri, B (2010). Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry, 167, 934994.Google Scholar
Baldwin, DS, Anderson, IM, Nutt, DJ, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 19, 567596.Google Scholar
Barbee, JG, Thompson, TR, Jamhour, NJ, et al. (2011). A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry, 72(10), 14051412. doi:10.4088/JCP.09m05355gre.Google Scholar
Barbosa, L, Berk, M, Vorster, M (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry, 64, 403407.Google Scholar
Bateman, DN (2003). Poisonous substances: antidepressants. Medicine, 31, 3234.CrossRefGoogle Scholar
Bauer, M, Dell’osso, L, Kasper, S, et al. (2013). Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord, 151(1), 209219. doi:10.1016/j.jad.2013.05.079.Google Scholar
Bauer, M, Adli, M, Ricken, R, Severus, E, Pilhatsch, M (2014). Role of lithium augmentation in the management of major depressive disorder. CNS Drugs, 28(4), 331342. doi:10.1007/s40263-014-0152-8.CrossRefGoogle ScholarPubMed
Baumann, P, Ulrich, S, Eckermann, G, et al. (2005). The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci, 7, 231247.Google Scholar
Berman, RM, Marcus, RN, Swanink, R, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 68, 843853.Google Scholar
Birkenhager, TK, van den Broek, WW, Moleman, P, Bruijn, JA (2006). Outcome of a 4-step treatment algorithm for depressed inpatients. J Clin Psychiatry, 67, 12661271.CrossRefGoogle ScholarPubMed
Blier, P, Gobbi, G, Turcotte, JE, et al. (2009). Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol, 19(7), 457465.CrossRefGoogle ScholarPubMed
Blier, P, Ward, HE, Tremblay, P, et al. (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry, 167(3), 281288.CrossRefGoogle ScholarPubMed
Bridge, JA, Iyengar, S, Salary, CB, et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 297, 16831696.Google Scholar
Brown, WA (2007). Treatment response in melancholia. Acta Psychiatr Scand, 115(Suppl 433), 125129.Google Scholar
Bryant, SG, Fisher, S, Kluge, RM (1987). Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system. J Clin Psychopharmacol, 7, 7882.Google Scholar
Buckley, NA, McManus, PR (2002). Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ, 325, 13321333.Google Scholar
Bukh, JD, Bock, C, Vinberg, M, Kessing, LV (2013). The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord, 145(1), 4248. doi:10.1016/j.jad.2012.07.008.Google Scholar
Bump, GM, Mulsant, BH, Pollock, BG, et al. (2001). Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety, 13, 3844.Google Scholar
Burke, WJ, Gergel, I, Bose, A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry, 63, 331336.Google Scholar
Byrne, SE, Rothschild, AJ (1998). Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry, 59, 279288.Google Scholar
Canuso, CM, Singh, JB, Fedgchin, M, et al. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry, 175, 620630. doi:10.1176/appi.ajp.2018.17060720.Google Scholar
Carpenter, LL, Yasmin, S, Price, LH (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry, 51, 183188.Google Scholar
Castro, VM, Clements, CC, Murphy, SN, et al. (2013). QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ, 346, f288. doi:10.1136/bmj.f288.Google Scholar
Cheeta, S, Schifano, F, Oyefeso, A, Webb, L, Ghodse, AH (2004). Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry, 184, 4147.CrossRefGoogle ScholarPubMed
Cheng, YL, Hu, HY, Lin, XH, et al. (2015). Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore), 94(46), e2022. doi:10.1097/MD.0000000000002022.Google Scholar
Cipriani, A, Hawton, K, Stockton, S, Geddes, JR (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646. https://doi.org/10.1136/bmj.f3646.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, TA, Salanti, G, et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391(10128), 13571366.CrossRefGoogle ScholarPubMed
Cleare, A, Pariante, CM, Young, AH, et al. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacology, 29(5), 459525.Google Scholar
Cramer, JA, Rosenheck, R (1998). Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49, 196201.Google Scholar
Crossley, NA, Bauer, M (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry, 68, 935940.Google Scholar
Dawson, R, Lavori, PW, Coryell, WH, Endicott, J, Keller, MB (1998). Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. J Affect Disord, 49, 3144.Google Scholar
de Abajo, FJ, Garcia-Rodriguez, LA (2008). Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry, 65, 795803.Google Scholar
Delgado, PL (2004). Common pathways of depression and pain. J Clin Psychiatry, 65(Suppl 12), 1619.Google Scholar
Delgado, PL, Brannan, SK, Mallinckrodt, CH, et al. (2005). Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry, 66, 686692.Google Scholar
Demyttenaere, K, Albert, A, Mesters, P, et al. (2005). What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry, 66, 859863.Google Scholar
Detke, MJ, Wiltse, CG, Mallinckrodt, CH, et al. (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol, 14, 457470.CrossRefGoogle ScholarPubMed
DeVeaugh-Geiss, AM, West, SL, Miller, WC, et al. (2010). The adverse effects of comorbid pain on depression outcomes in primary care patients: results from the ARTIST trial. Pain Med, 11(5), 732741. doi:10.1111/j.1526-4637.2010.00830.x.CrossRefGoogle ScholarPubMed
Dombrovski, AY, Mulsant, BH, Houck, PR, et al. (2007). Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord, 103, 7782.CrossRefGoogle ScholarPubMed
Dornseif, BE, Dunlop, SR, Potvin, JH, Wernicke, JF (1989). Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull, 25, 7179.Google Scholar
Dotoli, D, Spagnolo, C, Bongiorno, F, et al. (2006). Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables. Prog Neuropsychopharmacol Biol Psychiatry, 30, 442448.CrossRefGoogle Scholar
Dubini, A, Bosc, M, Polin, V (1997). Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol, 11, S17S23.Google ScholarPubMed
Edwards, JG, Anderson, I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs, 57(4), 507533.Google Scholar
El-Khalili, N, Joyce, M, Atkinson, S, et al. (2010). Extended-release quetiapine fumerate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol, 13, 917932.Google Scholar
Ezquiaga, E, Garcia, A, Bravo, F, Pallares, T (1998). Factors associated with outcome in major depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol, 33, 552557.CrossRefGoogle ScholarPubMed
Fava, GA, Ruini, C, Rafanelli, C, Grandi, S (2002). Cognitive behavior approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. Am J Psychiatry, 159, 20942095.CrossRefGoogle ScholarPubMed
Fava, M, Rappe, SM, Pava, JA, et al. (1995). Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry, 56, 5255.Google Scholar
Fava, M, Uebelacker, LA, Alpert, JE, et al. (1997). Major depressive subtypes and treatment response. Biol Psychiatry, 42, 568576.Google Scholar
Fava, M, Detke, MJ, Balestrieri, M, et al. (2006). Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res, 40, 328336.Google Scholar
Fava, M, Thase, ME, DeBattista, C, et al. (2007). Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry, 19, 153159.CrossRefGoogle ScholarPubMed
Fekadu, A, Wooderson, S, Donaldson, C, et al. (2009). A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry, 70, 177184.Google Scholar
Fekadu, A, Donocik, J, Cleare, AJ (2018). Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry, 18, 100. Available at: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-018-1679-x.Google Scholar
Fergusson, D, Doucette, S, Glass, KC, et al. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ, 330, 396.Google Scholar
Ferreri, M, Lavergne, F, Berlin, I, Payan, C, Puech, AJ (2001). Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand, 103, 6672.CrossRefGoogle ScholarPubMed
Flint, AJ, Rifat, SL (1998). Two-year outcome of psychotic depression in late life. Am J Psychiatry, 155, 178183.CrossRefGoogle ScholarPubMed
Fond, G, Loundou, A, Rabu, C, et al. (2014). Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl), 231(18), 36633676. doi:10.1007/s00213-014-3664-5.Google Scholar
Franchini, L, Gasperini, M, Zanardi, R, Smeraldi, E (2000a). Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord, 58, 233236.CrossRefGoogle ScholarPubMed
Franchini, L, Rossini, D, Bongiorno, F, et al. (2000b). Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Psychiatry Res, 96, 8185.CrossRefGoogle ScholarPubMed
Frank, E, Kupfer, DJ, Perel, JM, et al. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry, 47, 10931099.Google Scholar
Frank, E, Kupfer, DJ, Perel, JM, et al. (1993). Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord, 27, 139145.Google Scholar
Furukawa, TA, McGuire, H, Barbui, C (2002). Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ, 325, 991.Google Scholar
Geddes, JR, Carney, SM, Davies, C, et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653661.Google Scholar
Ghaziuddin, M, Ghaziuddin, N, Stein, GS (1990). Life events and the recurrence of depression. Can J Psychiatry, 35, 239242.CrossRefGoogle ScholarPubMed
Gibbons, RD, Brown, CH, Hur, K, et al. (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry, 164, 13561363.Google Scholar
Gijsman, HJ, Geddes, JR, Rendell, JM, et al. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry, 161 15371547.CrossRefGoogle ScholarPubMed
Goldstein, DJ, Lu, Y, Detke, MJ, et al. (2004). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol, 24, 389399.CrossRefGoogle ScholarPubMed
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30(6), 495553.Google Scholar
Greden, JF (1993). Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry, 54 Suppl, 3945.Google Scholar
Greist, J, McNamara, RK, Mallinckrodt, CH, Rayamajhi, JN, Raskin, J (2004). Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther, 26, 14461455.Google Scholar
Gunnell, D, Saperia, J, Ashby, D (2005). Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ, 330, 385.Google Scholar
Guo, T, Xiang, YT, Xiao, L, et al. (2015). Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry, 172(10), 10041013.CrossRefGoogle ScholarPubMed
Gusmao, R, Quintao, S, McDaid, D, et al. (2013). Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS One, 8, e66455.Google Scholar
Haddad, PM, Anderson, IM (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62, 16491671.Google Scholar
Halperin, D, Reber, G (2007). Influence of antidepressants on hemostasis. Dialogues Clin Neurosci, 9, 4759.Google Scholar
Hammerlein, A, Derendorf, H, Lowenthal, DT (1998). Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet, 35, 4964.Google Scholar
Hansen, R, Gaynes, B, Thieda, P, et al. (2008). Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv, 59(10), 11211130. doi:10.1176/appi.ps.59.10.1121.Google Scholar
Hawton, K, Bergen, H, Simkin, S, et al. (2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry, 196(5), 354358. doi:10.1192/bjp.bp.109.070219.Google Scholar
Healy, D, McMonagle, T (1997). The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol, 11, S25S31.Google ScholarPubMed
Henkel, V, Mergl, R, Allgaier, AK, et al. (2006). Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res, 141, 89101.Google Scholar
Hoffman, L, Enders, J, Luo, J, et al. (2003). Impact of an antidepressant management program on medication adherence. Am J Manag Care, 9, 7080.Google Scholar
Howland, RH (2010). Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv, 48, 912. doi:10.3928/02793695-20100527-98.Google Scholar
Iosifescu, DV, Nierenberg, AA, Alpert, JE, et al. (2004). Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics, 45, 419425.Google Scholar
Isbister, GK, Bowe, SJ, Dawson, A, Whyte, IM (2004). Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol, 42, 277285.Google Scholar
Jacobsen, PL, Mahableshwarkar, AR, Palo, WA, et al. (2016). Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr, 21, 367378.Google Scholar
Jick, H, Kaye, JA, Jick, SS (2004). Antidepressants and the risk of suicidal behaviors. JAMA, 292, 338343.Google Scholar
Joint Formulary Committee (2018). British National Formulary, 75th ed. London: BMJ Group and Pharmaceutical Press.Google Scholar
Kanai, T, Takeuchi, H, Furukawa, TA, et al. (2003). Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med, 33, 839845.Google Scholar
Karp, JF, Scott, J, Houck, P, et al. (2005). Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry, 66, 591597.Google Scholar
Katz, MM, Tekell, JL, Bowden, CL, et al. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology, 29, 566579.Google Scholar
Kessing, LV (1998). Recurrence in affective disorder. II. Effect of age and gender. Br J Psychiatry, 172, 2934.CrossRefGoogle ScholarPubMed
Kessing, LV (2003). Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Psychopathology, 36, 285291.Google Scholar
Kessing, LV (2007). Epidemiology of subtypes of depression. Acta Psychiatr Scand, 433 Suppl, 8589.Google Scholar
Kessing, LV, Andersen, PK (2005). Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Curr Psychiatry Rep, 7, 413420.Google Scholar
Kessler, D, Burns, A, Tallon, D, et al. (2018). Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess, 22(63), 1136.CrossRefGoogle ScholarPubMed
Köhler-Forsberg, O, Lydholm, N, Hjorthøj, C, et al. (2019). Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand, 139, 404419.CrossRefGoogle Scholar
Lader, M (1983). Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry, 44, 2024.Google ScholarPubMed
Lam, RW, Gorman, CP, Michalon, M, et al. (1995). Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry, 152, 17651770.Google Scholar
Landen, M, Bjorling, G, Agren, H, Fahlen, T (1998). A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry, 59, 664668.CrossRefGoogle ScholarPubMed
Lee, P, Shu, L, Xu, X, et al. (2007). Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci, 61, 295307.Google Scholar
Leinonen, E, Skarstein, J, Behnke, K, Agren, H, Helsdingen, JT (1999). Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol, 14, 329337.Google Scholar
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry, 200(2), 97106. doi:10.1192/bjp.bp.111.096594.Google Scholar
Leuchter, AF, Husain, MM, Cook, IA, et al. (2010). Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med, 40(2), 239251. doi:10.1017/S0033291709006035.Google Scholar
Licht, RW, Qvitzau, S (2002). Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl), 161, 143151.Google Scholar
Lonnqvist, J, Sihvo, S, Syvalahti, E, et al. (1995). Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr Scand, 91, 189194.CrossRefGoogle ScholarPubMed
Maes, M, Libbrecht, I, van Hunsel, F, Campens, D, Meltzer, HY (1999). Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol, 19, 177182.Google Scholar
Maidment, R, Livingston, G, Katona, C (2002). Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care. Int J Geriatr Psychiatry, 17(8), 752757.Google Scholar
Masand, PS, Gupta, S (2002). Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry, 14, 175182.Google Scholar
Mazure, CM, Bruce, ML, Maciejewski, PK, Jacobs, SC (2000). Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response. Am J Psychiatry, 157, 896903.Google Scholar
McAllister-Williams, RH, Christmas, D, Cleare, AJ, et al. (2018). Multiple-therapy-resistant-major depressive disorder: a clinically important concept. Br J Psychiatry, 212(5), 274278. doi:10.1192/bjp.2017.33.Google Scholar
McGirr, A, Berlim, MT, Bond, DJ, et al. (2015). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med, 45(4), 693704. doi:10.1017/S0033291714001603.Google Scholar
McGrath, PJ, Stewart, JW, Fava, M, et al. (2006a). Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry, 163, 15311541.Google Scholar
McGrath, PJ, Stewart, JW, Quitkin, FM, et al. (2006b). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry, 163, 15421548.Google Scholar
McLaughlin, T, Hogue, SL, Stang, PE (2007). Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther, 14, 221225.Google Scholar
Medhus, A, Heskestad, S, Tjemsland, L (1994). Mianserin added to tricyclic antidepressant in depressed patients not responding to a tricyclic antidepressant alone. A randomised, placebo-controlled, double-blind trial. Nord J Psychiatry, 48, 355358.Google Scholar
Medicines and Healthcare products Regulatory Agency (2011). Citalopram and escitalopram: QT interval prolongation (online). Available at: www.gov.uk/drug-safety-update/citalopram-and-escitalopram-qt-interval-prolongation (last accessed 16.10.19).Google Scholar
Melander, H, Salmonson, T, Abadie, E, et al. (2008). A regulatory Apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol, 18(9), 623627.Google Scholar
Modell, JG, Rosenthal, NE, Harriett, AE, et al. (2005). Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry, 58, 658667.Google Scholar
Montgomery, SA, Reimitz, PE, Zivkov, M (1998). Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol, 13, 6367.CrossRefGoogle ScholarPubMed
Morgan, ML, Cook, IA, Rapkin, AJ, Leuchter, AF (2005). Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry, 66, 774780.Google Scholar
Morgan, O, Griffiths, C, Baker, A, Majeed, A (2004). Fatal toxicity of antidepressants in England and Wales, 1993–2002. Health Stat Q, 23, 1824.Google Scholar
Moscovitch, A, Blashko, CA, Eagles, JM, et al. (2004). A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl), 171, 390397.Google Scholar
Mueller, TI, Leon, AC, Keller, MB, et al. (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry, 156, 10001006.Google Scholar
Murrough, JW, Iosifescu, DV, Chang, LC, et al. (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry, 170(10), 11341142. doi:10.1176/appi.ajp.2013.13030392.Google Scholar
Murrough, JW, Perez, AM, Pillemer, S, et al. (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 74(4), 250256. doi:10.1016/j.biopsych.2012.06.022.Google Scholar
National Institute for Clinical Excellence (2004). Depression: the management of depression in primary and secondary care. Clinical guideline [CG23]. Available at: www.nice.org.uk/guidance/cg23 (last accessed 20.10.19).Google Scholar
National Institute for Health and Clinical Excellence (NICE) (2009). Depression in adults: the treatment and management of depression in adults (update). Clinical guideline [CG90]. London: National Institute for Health and Care Excellence. Available at: www.nice.org.uk/guidance/cg90/chapter/1-guidance (last accessed 16.10.19).Google Scholar
Nelson, JC, Papakostas, GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry, 166(9), 980991. doi:10.1176/appi.ajp.2009.09030312.Google Scholar
Nelson, JC, Portera, L, Leon, AC (2005a). Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry, 57, 15351542.Google Scholar
Nelson, JC, Portera, L, Leon, AC (2005b). Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry, 66, 14091414.Google Scholar
Nierenberg, AA, McLean, NE, Alpert, JE, et al. (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry, 152, 15001503.Google ScholarPubMed
Nierenberg, AA, Farabaugh, AH, Alpert, JE, et al. (2000). Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry, 157, 14231428.Google Scholar
Nierenberg, AA, Fava, M, Trivedi, MH, et al. (2006). A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry, 163, 15191530.Google Scholar
Nurnberg, H, Hensley, PL, Heiman, JR, et al. (2008). Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA, 300, 395404.Google Scholar
Ohayon, MM, Schatzberg, AF (2003). Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry, 60, 3947.Google Scholar
Okuda, A, Suzuki, T, Kishi, T, et al. (2010). Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci, 64(3), 268273. doi:10.1111/j.1440-1819.2010.02091.x.Google Scholar
Pacchiarotti, I, Bond, DJ, Baldessarini, RJ, et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry, 170(11), 12491262. doi:10.1176/appi.ajp.2013.13020185.Google Scholar
Papakostas, GI, Fava, M, Thase, ME (2008). Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry, 63(7), 699704.Google Scholar
Parker, G (2000). Classifying depression: should paradigms lost be regained? Am J Psychiatry, 157, 11951203.Google Scholar
Partonen, T, Lonnqvist, J (1996). Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord, 41, 9399.Google Scholar
Paykel, ES, Tanner, J (1976). Life events, depressive relapse and maintenance treatment. Psychol Med, 6, 481485.Google Scholar
Paykel, ES, Ramana, R, Cooper, Z, et al. (1995). Residual symptoms after partial remission: an important outcome in depression. Psychol Med, 25, 11711180.Google Scholar
Perahia, DG, Wang, F, Mallinckrodt, CH, Walker, DJ, Detke, MJ (2006). Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry, 21, 367378.Google Scholar
Perahia, DG, Pritchett, YL, Kajdasz, DK, et al. (2008). A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res, 42, 2234.Google Scholar
Petersen, I, Gilbert, RE, Evans, SJ, Man, SL, Nazareth, I (2011). Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry, 72(7), 979985. doi:10.4088/JCP.10m06090blu.Google Scholar
Pope, HG Jr, Cohane, GH, Kanayama, G, Siegel, AJ, Hudson, JI (2003). Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry, 160(1), 105111.Google Scholar
Pope, HG, Amiaz, R, Brennan, BP, et al. (2010). Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol, 30(2), 126134. doi:10.1097/JCP.0b013e3181d207ca.Google Scholar
Posternak, MA, Zimmerman, M (2005). Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry, 66, 148158.Google Scholar
Posternak, MA, Zimmerman, M (2007). Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry, 190, 287292.Google Scholar
Posternak, MA, Solomon, DA, Leon, AC, et al. (2006). The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis, 194, 324329.Google Scholar
Quitkin, FM, Petkova, E, McGrath, PJ, et al. (2003). When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry, 160, 734740.Google Scholar
Raison, CL, Rutherford, RE, Woolwine, BJ, et al. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 70(1), 3141. doi:10.1001/2013.jamapsychiatry.4.Google Scholar
Ramana, R, Paykel, ES, Cooper, Z, et al. (1995). Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med, 25, 11611170.Google Scholar
Reimherr, FW, Amsterdam, JD, Quitkin, FM, et al. (1998). Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry, 155, 12471253.Google Scholar
Reimherr, FW, Strong, RE, Marchant, BK, Hedges, DW, Wender, PH (2001). Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. J Clin Psychiatry, 62(Suppl 22), 1623.Google Scholar
Reis, M, Aamo, T, Spigset, O, Ahlner, J (2009). Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit, 31(1), 4256. doi:10.1097/FTD.0b013e31819114ea.Google Scholar
Reynolds, CF, III, Perel, JM, Frank, E, et al. (1999). Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry, 156, 11771181.Google Scholar
Reynolds, CF, III, Dew, MA, Pollock, BG, et al. (2006). Maintenance treatment of major depression in old age. N Engl J Med, 354, 11301138.Google Scholar
Robinson, P, Katon, W, Von Korff, M, et al. (1997). The education of depressed primary care patients: what do patients think of interactive booklets and a video?J Fam Pract, 44, 562571.Google Scholar
Rojo, JE, Ros, S, Aguera, L, de la Gandara, J, de Pedro, JM (2005). Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl, 428, 2531.Google Scholar
Ronalds, C, Creed, F, Stone, K, Webb, S, Tomenson, B (1997). The outcome of anxiety and depressive disorders in general practice. Br J Psychiatry, 171, 427433.Google Scholar
Rouillon, F, Serrurier, D, Miller, HD, Gerard, MJ (1991). Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry, 52, 423431.Google Scholar
Rudolph, RL, Fabre, LF, Feighner, JP, et al. (1998). A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry, 59, 116122.Google Scholar
Ruhe, HG, Huyser, J, Swinkels, JA, Schene, AH (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry, 67, 18361855.Google Scholar
Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. (2006a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 163, 19051917.Google Scholar
Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. (2006b). Bupropion-SR, sertraline or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med, 354, 12311242.Google Scholar
Rush, AJ, Trivedi, MH, Stewart, JW, et al. (2011). Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry, 168, 689701.Google Scholar
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356(17), 17111722.Google Scholar
Sansone, RA, Sansone, LA (2012). Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci, 9(5–6), 4146.Google Scholar
Schindler, F, Anghelescu, IG (2007). Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol, 22, 179182.Google Scholar
Schmidt, ME, Fava, M, Zhang, S, et al. (2002). Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychother Psychosom, 71, 9094.Google Scholar
Schueler, Y-B, Koesters, M, Wieseler, B, et al. (2011). A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand, 123, 247265.Google Scholar
Schweizer, E, Rynn, M, Mandos, LA, et al. (2001). The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol, 16, 137143.CrossRefGoogle Scholar
Servier Laboratories Limited (2012). SPC for Valdoxan.Google Scholar
Simon, GE, Savarino, J (2007). Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry, 164, 10291034.Google Scholar
Simon, GE, Savarino, J, Operskalski, B, Wang, PS (2006). Suicide risk during antidepressant treatment. Am J Psychiatry, 163, 4147.Google Scholar
Solomon, DA, Keller, MB, Leon, AC, et al. (2000). Multiple recurrences of major depressive disorder. Am J Psychiatry, 157, 229233.Google Scholar
Solomon, DA, Leon, AC, Mueller, TI, et al. (2005). Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry, 66, 283290.Google Scholar
Spielmans, GI, Berman, MI, Linardatos, E, et al. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med, 10(3), e1001403.Google Scholar
Spina, E, Santoro, V, D’Arrigo, C (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther, 30(7), 12061227.Google Scholar
Stassen, HH, Angst, J, Delini-Stula, A (1996). Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry, 29, 8796.Google Scholar
Strawbridge, R, Carter, B, Marwood, L, et al. (2019). Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry, 214(1), 4251. doi:10.1192/bjp.2018.233.Google Scholar
Suppes, T, Silva, R, Cucchiaro, J, et al. (2016). Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry, 173, 400407.Google Scholar
Szegedi, A, Muller, MJ, Anghelescu, I, et al. (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry, 64, 413420.Google Scholar
Targownik, LE, Bolton, JM, Metge, CJ, Leung, S, Sareen, J (2009). Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol, 104(6), 14751482. doi:10.1038/ajg.2009.128.Google Scholar
Taylor, D, Cornelius, V, Smith, L, Young, AH (2014). Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand, 130(6), 452469. doi:10.1111/acps.12343.Google Scholar
Taylor, D, Barnes, TRE, Young, A (2018). The Maudsley Prescribing Guidelines in Psychiatry, 13th ed. Wiley-Blackwell.Google Scholar
Taylor, MJ, Freemantle, N, Geddes, JR, Bhagwagar, Z (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry, 63, 12171223.Google Scholar
Taylor, MJ, Rudkin, L, Bullemor-Day, P, et al. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev, (5), CD003382. doi:10.1002/14651858.CD003382.pub3.Google Scholar
Thanacoody, HK, Thomas, SH (2005). Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev, 24, 205214.Google Scholar
Thase, ME (2006). Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr, 11, 1221.Google Scholar
Thase, ME, Trivedi, MH, Rush, AJ (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacology, 12, 185219.Google Scholar
Thase, ME, Shelton, RC, Khan, A (2006). Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol, 26, 250258.Google Scholar
Thase, ME, Larsen, KG, Reines, E, Kennedy, SH (2013). The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol, 23(11), 13911400. doi:10.1016/j.euroneuro.2013.05.011.Google Scholar
Thase, ME, Mahableshwarkar, AR, Dragheim, M, Loft, H, Vieta, E (2016). A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol, 26, 979993.Google Scholar
Tint, A, Haddad, PM, Anderson, IM (2008). The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol, 22(3), 330332.Google Scholar
Tomaszewska, W, Peselow, ED, Barouche, F, Fieve, RR (1996). Antecedent life events, social supports and response to antidepressants in depressed patients. Acta Psychiatr Scand, 94, 352357.Google Scholar
Trivedi, MH, Fava, M, Wisniewski, SR, et al. (2006a). Medication augmentation after the failure of SSRIs for depression. N Engl J Med, 354, 12431252.Google Scholar
Trivedi, MH, Rush, AJ, Wisniewski, SR, et al. (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry, 163, 2840.Google Scholar
Uher, R, Maier, W, Hauser, J, et al. (2009). Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry, 194, 252259. doi:10.1192/bjp.bp.108.057554.Google Scholar
Vallejo, J, Gasto, C, Catalan, R, Bulbena, A, Menchon, JM (1991). Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators. J Affect Disord, 21, 151162.Google Scholar
Vergouwen, AC, Bakker, A, Katon, WJ, Verheij, TJ, Koerselman, F (2003). Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry, 64, 14151420.Google Scholar
Vieta, E, Bauer, M, Montgomery, S, et al. (2013). Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord, 150(2), 639643. doi:10.1016/j.jad.2013.01.052.Google Scholar
Walsh, BT, Seidman, SN, Sysko, R, Gould, M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA, 287, 18401847.Google Scholar
Walters, G, Reynolds, CF, III, Mulsant, BH, Pollock, BG (1999). Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry, 60(Suppl 20), 2125.Google Scholar
Walther, A, Breidenstein, J, Miller, R (2019). Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry, 76(1), 3140. doi:10.1001/jamapsychiatry.2018.2734.Google Scholar
Warden, D, Rush, AJ, Trivedi, MH, Fava, M, Wisniewski, SR (2007). The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep, 9(6), 449459.Google Scholar
Wijkstra, J, Lijmer, J, Balk, JF, Geddes, JR., Nolen, WA (2006). Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry, 188(5), 410415.Google Scholar
Wohlreich, MM, Mallinckrodt, CH, Watkin, JG, et al. (2005). Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry, 17, 259268.Google Scholar
Yildiz, A, Pauler, DK, Sachs, GS (2004). Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. J Affect Disord, 78, 157162.Google Scholar
Yyldyz, A, Sachs, GS (2001). Administration of antidepressants. Single versus split dosing: a meta-analysis. J Affect Disord, 66, 199206.Google Scholar
Zarrouf, FA, Artz, S, Griffith, J, Sirbu, C, Kommor, M (2009). Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract, 15(4), 289305. doi:10.1097/01.pra.0000358315.88931.fc.Google Scholar
Zheng, W, Li, X-H, Zhu, X-M, et al. (2019). Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: a meta-analysis of randomized controlled trials. J Affective Disord, 250, 123131.Google Scholar
Zhou, X, Ravindran, AV, Qin, B, et al. (2015). Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. Clin Psychiatry, 76(4), e487e498. doi:10.4088/JCP.14r09204.Google Scholar
Zivin, K, Pfeiffer, PN, Bohnert, AS, et al. (2013). Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry, 170(6), 642650. doi:10.1176/appi.ajp.2013.12030408.Google Scholar

References

Argolo, FC, Cavalcanti-Ribeiro, P, Netto, LR, Quarantini, LC (2015). Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J Psychosom Res, 79, 8993.Google Scholar
Baldwin, DS, Aitchison, KBA, Curran, HV, et al. (2013). Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol, 27, 967971.Google Scholar
Baldwin, DS, Anderson, IM, Nutt, DJ, et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol, 28, 403439.Google Scholar
Baldwin, DS, den Boer, JA, Lyndon, G, et al. (2015). Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol, 29, 10471060.CrossRefGoogle ScholarPubMed
Bandelow, B, Reitt, M, Röver, C, et al. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol, 30, 183192.Google Scholar
Bandelow, B, Baldwin, D, Abelli, M, et al. (2017). Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry, 18, 162214.Google Scholar
Barker, MJ, Greenwood, KM, Jackson, M, Crowe, SF (2004). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol, 19, 437454.Google Scholar
Batelaan, NM, Bosman, RC, Muntingh, A, et al. (2017). Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ, 358, j3927.Google Scholar
Billioti de Gage, S, Pariente, A, Bégaud, B (2015). Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf, 14, 733747.Google Scholar
Bonnet, U, Scherbaum, N (2017). How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol, 27, 11851215.Google Scholar
Chagraoui, A, Skiba, M, Thuillez, C, Thibaut, F (2016). To what extent is it possible to dissociate the anxiolytic and sedative/hypnotic properties of GABAA receptors modulators? Prog Neuropsychopharmacol Biol Psychiatry, 71, 189202.Google Scholar
Chessick, CA, Allen, MH, Thase, ME, et al. (2006). Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev, (3), CD006115.Google Scholar
Corchs, F, Nutt, DJ, Hince, DA, et al. (2015). Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans? J Psychopharmacol, 29, 10611069.Google Scholar
Cowen, PJ, Anderson, IM, Grahame-Smith, DG (1990). Neuroendocrine effects of azapirones. J Clin Psychopharmacol, 10, 21S25S.Google Scholar
Culpepper, L, Wingertzahn, MA (2015). Over-the-counter agents for the treatment of occasional disturbed sleep or transient insomnia: a systematic review of efficacy and safety. Prim Care Companion CNS Disord, 17, 10.4088/PCC.15r01798.Google Scholar
Deakin, JFW (2013). The origins of ‘5-HT and mechanisms of defence’ by Deakin and Graeff: a personal perspective. J Psychopharmacol, 27, 10841089.Google Scholar
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol, 18, pii: pyv047. doi:10.1093/ijnp/pyv047.Google Scholar
Drover, DR (2004). Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives. Clin Pharmacokinet, 43, 227238.Google Scholar
Ducasse, D, Boyer, L, Michel, P, et al. (2014). D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology (Berl), 231, 37653770.Google Scholar
Dündar, Y, Dodd, S, Strobl, J, et al. (2004). Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol, 19, 305322.Google Scholar
Fleminger, S, Greenwood, RRJ, Oliver, DL (2006). Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev, (4), CD003299.Google Scholar
Freynhagen, R, Backonja, M, Schug, S, et al. (2016). Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs, 30, 11911200.Google Scholar
Goodwin, GM, Emsley, R, Rembry, S, et al. (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 70, 11281137.Google Scholar
Haddad, PM, Anderson, IM (2007). Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat, 13, 447457.Google Scholar
Hajak, G, Müller, WE, Wittchen, HU, Pittrow, D, Kirch, W (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction, 98, 13711378.Google Scholar
Kalueff, AV, Nutt, DJ (2007). Role of GABA in anxiety and depression. Depress Anxiety, 24, 495517.Google Scholar
Kishi, T, Meltzer, HY, Matsuda, Y, Iwata, N (2013). Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis. Psychol Med, 44, 22552269.Google Scholar
Kishi, T, Matsunaga, S, Iwata, N (2015). Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PLoS One, 10, e0136910.Google Scholar
Kuriyama, A, Honda, M, Hayashino, Y (2014). Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med, 15, 385392.Google Scholar
Loane, C, Politis, M (2012). Buspirone: what is it all about? Brain Res, 1461, 111118.Google Scholar
Maneeton, N, Maneeton, B, Woottiluk, P, et al. (2016). Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther, 10, 259276.Google Scholar
Micó, J-A, Prieto, R (2012). Elucidating the mechanism of action of pregabalin. CNS Drugs, 26, 637648.Google Scholar
Miller, CH, Fleischhacker, WW (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Saf, 22, 7381.Google Scholar
Muscatello, MR, Spina, E, Bandelow, B, Baldwin, DS (2012). Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol, 27, 239253.Google Scholar
Peterlik, D, Flor, PJ, Uschold-Schmidt, N (2016). The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders. Curr Neuropharmacol, 14, 514539.Google Scholar
Pignon, B, Tezenas du Montcel, C, Carton, L, Pelissolo, A (2017). The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep, 19, 103.Google Scholar
Pitsikas, N (2014). The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders? Eur J Pharmacol, 723, 181184.Google Scholar
Schjerning, O, Rosenzweig, M, Pottegård, A, Damkier, P, Nielsen, J (2016). Abuse potential of pregabalin. CNS Drugs, 30, 925.Google Scholar
Sieghart, W, Sperk, G (2002). Subunit composition, distribution and function of GABA-A receptor subtypes. Curr Top Med Chem, 2, 795816.Google Scholar
Sigel, E, Steinmann, ME (2012). Structure, function and modulation of GABAA receptor. J Biol Chem, 287, 4022440231.Google Scholar
Soyka, M (2017). Treatment of benzodiazepine dependence. N Engl J Med, 376, 11471157.Google Scholar
Steenen, SA, van Wijk, AJ, van der Heijden, GJ, et al. (2016). Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol, 30, 128139.Google Scholar
Stein, DJ, Ahokas, AA, de Bodinat, C (2008). Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol, 28, 561566.Google Scholar
Stein, DJ, Ahokas, A, Albarran, C, et al. (2012). Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry, 73, 10021008.Google Scholar
Sutton, JA, Clauss, RP (2017). A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: a justification of further clinical trials. Brain Inj, 31, 10191027.Google Scholar
Turner, P, Granville-Grossman, KL, Smart, JV (1965). Effect of adrenergic receptor blockade on the tachycardia of thyrotoxicosis and anxiety state. Lancet, 286, 13161318.Google Scholar
Walsh, JK, Krystal, AD, Amato, DA, et al. (2007). Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep, 30, 959968.CrossRefGoogle ScholarPubMed
Whale, R, Terao, T, Cowen, P, Freemantle, C, Geddes, G (2010). Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol, 24, 513520.Google Scholar
Wilson, SJ, Nutt, DJ, Alford, C, et al. (2010). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol, 24, 15771601.Google Scholar
Yeung, W-F, Chung, K-F, Yung, K-P, Ng, TH-Y (2015). Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev, 19, 7583.Google Scholar

References

Adams, CE, Fenton, MK, Quraishi, S, David, AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry, 179, 290299.Google Scholar
Arranz, MJ, Rivera, M, Munro, JC (2011). Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs, 25(11), 933939.Google Scholar
Ashok, AH, Marques, TR, Jauhar, S, et al. (2017). The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry, 22(5), 666679.Google Scholar
Bagnall, AM, Jones, L, Ginnelly, L, et al. (2003). A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess, 7(13), 1193.Google Scholar
Beck, K, McCutcheon, R, Bloomfield, MAP, et al. (2014). The practical management of refractory schizophrenia – the Maudsley Treatment Review and Assessment Team service approach. Acta Psychiatr Scand, 130(6), 427438.Google Scholar
Beresford, R, Ward, A (1987). Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs, 33(1), 3149.Google Scholar
Bleakley, S (2012). Identifying and reducing the risk of antipsychotic drug interactions. Prog Neurol Psychiatry, 16(2), 2024.Google Scholar
Bolden, C, Cusack, B, Richelson, E (1992). Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther, 260(2), 576580.Google Scholar
Brugger, SP, Howes, OD (2017). Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis. JAMA Psychiatry, 74(11), 11041111.Google Scholar
Buckley, PF, Schooler, NR, Goff, DC, et al. (2016). Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv, 67(12), 13701372.Google Scholar
Bymaster, FP, Calligaro, DO, Falcone, JF, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 8796.Google Scholar
Carbon, M, Kane, MJ, Leucht, S, Correll, CU (2018). Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry, 17(3), 330340. doi:10.1002/wps.20579.Google Scholar
Carlsson, A, Lindqvist, M (1963). Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh), 20(2), 140144.Google Scholar
Cipriani, A, Barbui, C, Salanti, G, et al. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378(9799), 13061315.Google Scholar
Correll, CU (2010). From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry, 25(Suppl 2), S12S21. doi:10.1016/S0924-9338(10)71701-6.Google Scholar
Correll, CU, Citrome, L, Haddad, PM, et al. (2016). The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry, 77(Suppl 3), 124.Google Scholar
Creese, I, Burt, D, Snyder, S (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192(4238), 481483.Google Scholar
Davidson, M, Saoud, J, Staner, C, et al. (2017). Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry, 174(12), 11951202.Google Scholar
Davies, DL, Shepherd, M (1955). Reserpine in the treatment of anxious and depressed patients. Lancet, 269(6881), 117120.Google Scholar
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol, 18(9), pyv047.Google Scholar
Douglas, IJ, Smeeth, L (2008). Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ, 337, a1227.Google Scholar
Dzahini, O, Singh, N, Taylor, D, Haddad, PM (2018). Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol, 32(11), 11671181.Google Scholar
Emsley, R, Medori, R, Koen, L, et al. (2008). Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol, 28(2), 210213.Google Scholar
Fallon, P, Dursun, S, Deakin, B (2012). Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol, 2(1), 1322.Google Scholar
Frampton, JE (2010). Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs, 70(17), 22892313.Google Scholar
González-Blanco, L, Greenhalgh, AMD, Garcia-Rizo, C, et al. (2016). Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res, 174(1), 156160.Google Scholar
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30(6), 495553.Google Scholar
Grace, AA, Gomes, FV (2019). The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophr Bull, 45(1), 148157. doi:10.1093/schbul/sbx199.Google Scholar
Graff-Guerrero, A, Mizrahi, R, Agid, O, et al. (2009). The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology, 34(4), 10781086.Google Scholar
Graff-Guerrero, A, Mamo, D, Shammi, C, et al. (2013). The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11c]-(+)-PHNO. Arch Gen Psychiatry, 66(6), 606615.Google Scholar
Grossman, I, Sullivan, PF, Walley, N, et al. (2008). Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med, 10(10), 720729.Google Scholar
Haddad, PM, Anderson, IM (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62(11), 16491671.Google Scholar
Haddad, PM, Correll, CU (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol, 8(11), 303318.Google Scholar
Haddad, PM, Wieck, A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 22912314.Google Scholar
Hedges, D, Jeppson, K, Whitehead, P (2003). Antipsychotic medication and seizures: a review. Drugs Today (Barc), 39(7), 551557.Google Scholar
Heres, S, Hamann, J, Kissling, W, Leucht, S (2006). Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry, 67(12), 19481953.Google Scholar
Hirsch, SR, Gaind, R, Rohde, PD, Stevens, BC, Wing, JK (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo. Br Med J, 1(5854), 633637.Google Scholar
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry, 68(2), 128137.Google Scholar
Horvitz-Lennon, M, Mattke, S, Predmore, Z, Howes, OD (2017). The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry, 174(5), 421426.Google Scholar
Howes, OD, Kapur, S (2014). A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type b (normodopaminergic). Br J Psychiatry, 205, 13.Google Scholar
Howes, OD, McCutcheon, R. (2017). Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry, 7(2), e1024. doi:10.1038/tp.2016.278.Google Scholar
Howes, OD, Kambeitz, J, Kim, E, et al. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry, 69(8), 776786.Google Scholar
Howes, O, McCutcheon, R, Stone, J (2015). Glutamate and dopamine in schizophrenia: an update for the 21(st) century. J Psychopharmacol, 29(2), 97115.Google Scholar
Howes, OD, McCutcheon, R, Agid, O, et al. (2017a). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174(3), 216229.Google Scholar
Howes, OD, McCutcheon, R, Owen, MJ, Murray, RM (2017b). The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry, 81(1), 920.Google Scholar
Jauhar, S, Veronese, M, Rogdaki, M, et al. (2017). Regulation of dopaminergic function: an [18 F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry, 7(2), e1027. doi:10.1038/tp.2016.270.Google Scholar
Johnsen, E, Kroken, RA, Abaza, M, Olberg, H, Jørgensen, HA (2008). Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol, 28(6), 686690. doi:10.1097/JCP.0b013e31818ba5d8.Google Scholar
Johnson, DAW (2009). Historical perspective on antipsychotic long-acting injections. Br J Psychiatry, 195(52), S7S12.Google Scholar
Kane, JM, Detke, HC, Naber, D, et al. (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry, 167(2), 181189.Google Scholar
Kapur, S (1998). A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry, 3(2), 135140.Google Scholar
Kapur, S, Seeman, P (2000). Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci, 25(2), 161166.Google Scholar
Kapur, S, Seeman, P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry, 158(3), 360369.Google Scholar
Kapur, S, Zipursky, RB, Remington, G, et al. (1998). 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry, 155(7), 921928.Google Scholar
Kapur, S, Zipursky, RB, Remington, G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry, 156(2), 286293.Google Scholar
Kapur, S, Zipursky, R, Jones, C, Remington, G, Houle, S (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157(4), 514520.Google Scholar
Kebabian, JW, Calne, DB (1979). Multiple receptors for dopamine. Nature, 277(5692), 9396.Google Scholar
Kim, B, Lee, SH, Choi, TK, et al. (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry, 32(5), 12311235. doi:10.1016/j.pnpbp.2008.03.012.Google Scholar
King, C, Voruganti, LNP (2002). What’s in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci, 27(3), 168175.Google Scholar
Kirson, NY, Weiden, PJ, Yermakov, S, et al. (2013). Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry, 74(6), 568575.Google Scholar
Kisely, S, Sawyer, E, Robinson, G, Siskind, D (2015). A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. Schizophr Res, 166(1–3), 178186.Google Scholar
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull, 40(1), 192213.Google Scholar
Kwentus, J, Riesenberg, RA, Marandi, M, et al. (2012). Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord, 14(1), 3140. doi:10.1111/j.1399-5618.2011.00975.x.Google Scholar
Laborit, H, Huguenard, P, Alluaume, R (1952). Un noveau stabilisateur végétatif (le 4560 RP). La Presse Médicale, 60, 206–208.Google Scholar
Lambert, M, Conus, P, Eide, P, et al. (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry, 19(7), 415422.Google Scholar
Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, et al. (2011). Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry, 198(1), 5158. doi:10.1192/bjp.bp.110.081513.Google Scholar
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 35(1), 5168.Google Scholar
Leucht, S, Busch, R, Kissling, W, Kane, JM (2007). Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry, 68(3), 352360.Google Scholar
Leucht, S, Corves, C, Arbter, D, et al. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373(9657), 3141.Google Scholar
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM (2012a). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry, 200(2), 97106.Google Scholar
Leucht, S, Tardy, M, Komossa, K, et al. (2012b). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev, (5), CD008016.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382(9896), 951962.Google Scholar
Leucht, S, Leucht, C, Huhn, M, et al. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry, 174(10), 927942.Google Scholar
Lieberman, JA, 3rd (2004). Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry, 6(Suppl 2), 2023.Google Scholar
Lindström, L, Lindström, E, Nilsson, M, Höistad, M (2017). Maintenance therapy with second generation antipsychotics for bipolar disorder – a systematic review and meta-analysis. J Affect Disord, 213, 138150. doi:10.1016/j.jad.2017.02.012.Google Scholar
Mallikaarjun, S, Kane, JM, Bricmont, P, et al. (2013). Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res, 150(1), 281288.Google Scholar
Maneeton, N, Maneeton, B, Woottiluk, P, et al. (2016). Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther, 10, 259276. doi:10.2147/DDDT.S89485.Google Scholar
Marder, SR, Hubbard, JW, Van Putten, T, Midha, KK (1989). Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology, 98(4), 433439.Google Scholar
Mauri, MC, Volonteri, LS, Colasanti, A, et al. (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet, 46(5), 359388.Google Scholar
McCutcheon, R, Beck, K, Bloomfield, MA, et al. (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol, 29(8), 892897.Google Scholar
McCutcheon, R, Beck, K, D’Ambrosio, E, et al. (2017). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand, 137(1), 3946.Google Scholar
McCutcheon, R, Beck, K, Jauhar, S, Howes, OD (2018). Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull, 44(6), 13011311.Google Scholar
McCutcheon, RA, Abi-Dargham, A, Howes, OD (2019). Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci, 42(3), 205220.Google Scholar
Meltzer, HY, Matsubara, S, Lee, J-C (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine. J Pharmacol Exp Ther, 251(1), 238246.Google Scholar
Minzenberg, MJ, Poole, JH, Benton, C, Vinogradov, S (2004). Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry, 161(1), 116124.Google Scholar
Murphy, BP, Chung, Y-C, Park, T-W, McGorry, PD (2006). Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res, 88(1–3), 525.Google Scholar
Murray, RM, Quattrone, D, Natesan, S, et al. (2016). Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry, 209(5), 361365.Google Scholar
Nyberg, S, Farde, L, Eriksson, L, Halldin, C, Eriksson, B (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology, 110(3), 265272.Google Scholar
Oehl, M, Hummer, M, Fleischhacker, WW (2000). Compliance with antipsychotic treatment. Acta Psychiatr Scand, 102, 8386.Google Scholar
Olianas, MC, Maullu, C, Onali, P (1997). Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol, 122(3), 401408.Google Scholar
Ortiz-Orendain, J, Castiello-de Obeso, S, Colunga-Lozano, LE, et al. (2017). Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev, (6), CD009005. doi:10.1002/14651858.CD009005.pub2.Google Scholar
Pantelis, C, Velakoulis, D, McGorry, PD, et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361(9354), 281288.Google Scholar
Park, EJ, Amatya, S, Kim, MS, et al. (2013). Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res, 36(6), 651659.Google Scholar
Parsons, B, Allison, DB, Loebel, A, et al. (2009). Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res, 110(1–3), 103110.Google Scholar
Pelonero, AL, Levenson, JL, Pandurangi, AK (1998). Neuroleptic malignant syndrome: a review. Psychiatr Serv, 49(9), 11631172.Google Scholar
Perreault, ML, Hasbi, A, Alijaniaram, M, et al. (2010). The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem, 285(47), 3662536634.Google Scholar
Ravyn, D, Ravyn, V, Lowney, R, Nasrallah, HA (2013). CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res, 149(1–3), 114.Google Scholar
Ronaldson, KJ (2017). Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs, 31(9), 777795.Google Scholar
Rummel-Kluge, C, Komossa, K, Schwarz, S, et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res, 123(2–3), 225233.Google Scholar
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356, 17111722. doi:10.1056/NEJMoa064135.Google Scholar
Samara, MT, Dold, M, Gianatsi, M, et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73(3), 199210.Google Scholar
Seeman, P (2001). Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin Neurosci Res, 1(1–2), 5360.Google Scholar
Seeman, P (2011). All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther, 17(2), 118132.Google Scholar
Seeman, P (2012). Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse, 66(1), 8893.Google Scholar
Seeman, P, Chau-Wong, M, Tedesco, J, Wong, K (1975). Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A, 72(11), 43764380.Google Scholar
Sepede, G, De Berardis, D, Gambi, F, et al. (2006). Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol, 26(1), 4549.Google Scholar
Shen, WW (1999). A history of antipsychotic drug development. Compr Psychiatry, 40, 407414.Google Scholar
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 209(5), 385392.Google Scholar
Slifstein, M, van de Giessen, E, Van Snellenberg, J, et al. (2015). Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry, 72(4), 316324.Google Scholar
Soderberg, MM, Dahl, ML (2013). Pharmacogenetics of olanzapine metabolism. Pharmacogenomics, 14(11), 13191336.Google Scholar
Soldin, OP, Mattison, DR (2009). Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet, 48(3), 143157.Google Scholar
Spielmans, GI, Berman, MI, Linardatos, E, et al. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med, 10(3), e1001403.Google Scholar
Spina, E, de Leon, J (2007). Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol, 100(1), 422.Google Scholar
Stein, G, Wilkinson, G (eds.) (2007). Seminars in General Adult Psychiatry, 2nd ed. London: Royal College of Psychiatrists.Google Scholar
Taylor, D (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry, 195(52), S13S19.Google Scholar
Tiihonen, J, Haukka, J, Taylor, M, et al. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry, 168(6), 603609.Google Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686693.Google Scholar
Veijola, J, Guo, JY, Moilanen, JS, et al. (2014). Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One, 9(7), e101689.Google Scholar
Weiden, PJ, Schooler, NR, Weedon, JC, et al. (2009). A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry, 70(10), 13971406. doi:10.4088/JCP.09m05284yel.Google Scholar
Weinberger, DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry, 44(7), 660669.Google Scholar
Wijkstra, J, Lijmer, J, Burger, H, et al. (2015). Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev, (7), CD004044.Google Scholar
Wu, CS, Wang, SC, Yeh, IJ, Liu, SK (2016). Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry, 77(5), e573e579.Google Scholar
Young, SL, Taylor, M, Lawrie, SM (2015). ‘First do no harm.’ A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol, 29(4), 353362.Google Scholar
Zeng, XP, Le, F, Richelson, E (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol, 321(3), 349354.Google Scholar
Zhang, ZJ, Yao, ZJ, Liu, W, Fang, Q, Reynolds, GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry, 184, 5862.Google Scholar
Zhu, Y, Li, C, Huhn, M, et al. (2017). How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 27(9), 835844. doi:10.1016/j.euroneuro.2017.06.011.Google Scholar
Zohar, J, Stahl, S, Moller, H-J, et al. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol, 25(12), 23182325.Google Scholar

References

Agid, O, Arenovich, T, Sajeev, G, et al. (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry, 72, 14391444.Google Scholar
Bagnall, AM, Jones, L, Ginnelly, L, et al. (2003). A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess, 7(13), 1193.Google Scholar
Barber, S, Olotu, U, Corsi, M, Cipriani, A (2017). Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev, (3), CD006324.Google Scholar
Barnes, TR; Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011). Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 25, 567620.Google Scholar
Barnes, TRE, Drake, RJ, Dunn, G, et al. (2013). The effect of prior treatment with long-acting injectable antipsychotic drugs on randomised, clinical trial treatment outcomes. Br J Psychiatry, 203(3), 215220.Google Scholar
Barnes, TRE, Dye, S, Ferrier, N, et al. (2014). Consensus Statement on High-Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists.Google Scholar
Beri, A, Boydell, J (2014). Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry, 26(2), 139144.Google Scholar
Bowskill, S, Couchman, L, MacCabe, JH, Flanagan, RJ (2012). Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996–2010. Hum Psychopharmacol, 27(3), 277283.Google Scholar
Brosda, J, Jantschak, F, Pertz, HH (2014). Alpha2-adrenoceptors are targets for antipsychotic drugs. Psychopharmacology, 231(5), 801812.Google Scholar
Chang, A, Fox, SH (2016). Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs, 76(11), 10931118.Google Scholar
Chang, JS, Ha, KS, Young Lee, K, Sik Kim, Y, Min Ahn, Y (2006). The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry, 67(3), 461467.Google Scholar
Cohen, D (2017). Clozapine and gastrointestinal hypomotility. CNS Drugs, 31(12), 10831091.Google Scholar
Cohen, D, Bogers, JP, van Dijk, D, Bakker, B, Schulte, PF (2012). Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry, 73(10), 13071312.Google Scholar
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry, 74, 675684.Google Scholar
Couchman, L, Morgan, EL, Spencer, EP, Flanagan, RJ (2010). Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit, 32, 438447.Google Scholar
Crilly, J (2007). The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry, 18(1), 3960.Google Scholar
Davies, LM, Lewis, S, Jones, PB, et al.; CUtLASS team (2007). Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry, 191, 1422.Google Scholar
Davis, JM, Chen, N, Glick, ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 60(6), 553564.Google Scholar
Demjaha, A, Egerton, A, Murray, RM, et al. (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry, 75(5), e11e13.Google Scholar
Dzahini, O, Singh, N, Taylor, D, Haddad, PM (2018). Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol, 32(11), 11671181.Google Scholar
electronic Medicines Compendium (2019). Summary of Product Characteristics: Clorazil. Mylan. Last updated 6 June 2019. Available at: www.medicines.org.uk/emc/product/10290/smpc (last accessed 4.10.19).Google Scholar
Fabrazzo, M, La Pia, S, Monteleone, P, et al. (2002). Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology, 27(6), 10501055.Google Scholar
Foley, DL, Mackinnon, A, Morgan, VA, et al. (2015). Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry, 2(12), 10921098.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M (2011). A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol, 15(9), 13511371.Google Scholar
Galling, B, Roldán, A, Hagi, K, et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.World Psychiatry, 16(1), 7789.Google Scholar
Goldstein, ME, Anderson, VM, Pillai, A, Kydd, RR, Russell, BR (2015). Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol, 18(6), 117.Google Scholar
Gross, G, Wicke, K, Drescher, KU (2013). Dopamine D3 receptor antagonism – still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol, 386(2), 155166.Google Scholar
Haddad, PM, Correll, CU (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol, 8(11), 303318.Google Scholar
Haddad, PM, Wieck, A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 22912314.Google Scholar
Hampson, M, Killaspy, H, Mynors-Wallis, L, Meier, R (2011). Outcome measures recommended for use in adult psychiatry. Occasional Paper OP78. London: Royal College of Psychiatrists. Available at: www.rcpsych.ac.uk/files/pdfversion/OP78x.pdf (last accessed 11.8.17).Google Scholar
Healy, D (1997). The Psychopharmcologists: Interviews by David Healy. New York: Chapman and Hall.Google Scholar
Holt, RIG, Peveler, RC (2009). Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metabol, 11, 665679.Google Scholar
Howes, OD, Vergunst, F, Gee, S, et al. (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry, 201, 481485.Google Scholar
Howes, OD, McCutcheon, R, Agid, O, et al. (2017). Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174(3), 216229.Google Scholar
Huang, KL, Fang, CJ, Hsu, CC, et al. (2017). Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol, 31(12), 15441555. doi:10.1177/0269881117714047.Google Scholar
Hung, GC, Liu, HC, Yang, SY, et al. (2016). Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. J Clin Psychiatry, 77, 6066.Google Scholar
Hynes, C, Keating, D, McWilliams, S, et al. (2015). Glasgow Antipsychotic Side-effects Scale for Clozapine – development and validation of a clozapine-specific side-effects scale. Schizophr Res, 168(1–2), 505513.Google Scholar
Ifteni, P, Nielsen, J, Burtea, V, et al. (2014). Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand, 130, 2529.Google Scholar
Ismail, Z, Wessels, AM, Uchida, H, et al. (2012). Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry, 20(1), 5360.Google Scholar
Kane, JM, Honigfield, G, Singer, J, Meltzer, HY (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789796.Google Scholar
Kluge, M, Schuld, A, Schacht, A, et al. (2009). Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology, 34(1), 118128.Google Scholar
Koponen, HJ, Hakko, HH, Saari, KM, et al. (2010). The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry, 11(2 Pt 2), 262267.Google Scholar
Krawiecka, M, Goldberg, D, Vaughan, M. (1977). A standardised psychiatric assessment scale for rating chronic psychiatric patients. Acta Psychiatr Scand, 55, 299308.Google Scholar
Kuo, CJ, Yang, SY, Liao, YT, et al. (2013). Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull, 39, 648657.Google Scholar
Lahti, RA, Evans, DL, Stratman, NC, Figur, LM (1993). Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol, 236(3), 483486.Google Scholar
Lalanne, L, Lutz, PE, Trojak, B, et al. (2016). Medications between psychiatric and addictive disorders. Prog Neuropsychopharmacol Biol Psychiatry, 65, 215223.Google Scholar
Lally, J, Tully, J, Robertson, D, et al. (2016). Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res, 171(1–3), 215224.Google Scholar
Lambert, M, Haro, JM, Novick, D, et al. (2005). Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand, 111(3), 232243.Google Scholar
Lambiase, PD, de Bono, JP, Schilling, RJ, et al. (2019). British Heart Rhythm Society clinical practice guidelines on the management of patients developing QT prolongation on antipsychotic medication. Arrhythm Electrophysiol Rev, 8(3), 161165.Google Scholar
Laroche, DG, Gaillard, A (2016). Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses. Psychiatry Res, 246, 119128.Google Scholar
Leucht, S, Cipriani, A, Spijeli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951962.Google Scholar
Lewis, SW, Barnes, TR, Davies, L, et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull, 32(4), 715723.Google Scholar
Li, XB, Tang, YL, Wang, CY, et al. (2015). Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord, 17, 235247.Google Scholar
Lieberman, JA, Phillips, M, Gu, H, et al. (2003). Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology, 28(5), 9951003.Google Scholar
Lobos, CA, Komossa, K, Rummel-Kluge, C, et al. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, (11), CD006633.Google Scholar
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU (2012). When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res, 134(2–3), 180186.Google Scholar
Manu, P, Lapitskaya, Y, Shaikh, A, Nielsen, J (2018). Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther, 25(2), e218e223.Google Scholar
Mauri, MC, Volonteri, LS, Colasanti, A, et al. (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet, 46(5), 359388.Google Scholar
McEvoy, JP, Lieberman, JA, Stroup, TS, et al.; CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163(4), 600610.Google Scholar
Melkersson, K, Lewitt, M, Hall, K (2015). Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro Endocrinol Lett, 36(5), 465480.Google Scholar
Meltzer, HY (2013). Update on typical and atypical antipsychotic drugs. Annu Rev Med, 64, 393406.Google Scholar
Meltzer, HY, Alphs, L, Green, AI, et al.; International Suicide Prevention Trial Study Group (2003). Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry, 60, 8291.Google Scholar
Mendoza, MC, Lindenmayer, JP (2009). N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol, 32(3), 154157.Google Scholar
Meyer, N, Gee, S, Whiskey, E, et al. (2015). Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry, 76(11), e1410e1416.Google Scholar
Miyamoto, S, Miyake, N, Jarskog, LF, Fleischhacker, WW, Lieberman, JA (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry, 17(12), 12061227.Google Scholar
Morrison, AP, Pyle, M, Gumley, A, et al. (2019). Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health Technol Assess, 23(7), 1144.Google Scholar
Mouchlianitis, E, Bloomfield, MA, Law, V, et al. (2016). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull, 42(3), 744752.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. London: National Institute for Health and Care Excellence. Available at: www.nice.org.uk/guidance/cg178 (last accessed 4.10.19).Google Scholar
Nielsen, J, Meyer, JM (2012). Risk factors for ileus in patients with schizophrenia. Schizophr Bull, 38(3), 592598.Google Scholar
Nielsen, J, Correll, CU, Manu, P, Kane, JM (2013). Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry, 74(6), 603613.Google Scholar
Norman, SM, Sullivan, KM, Liu, F, et al. (2017). Blood pressure and heart rate changes during clozapine treatment. Psychiatr Q, 88(3), 545552.Google Scholar
Novick, D, Haro, JM, Perrin, E, Suarez, D, Texeira, JM (2009). Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol, 19(8), 542550.Google Scholar
O’Connor, WT, O’Shea, SD (2015). Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacol Ther, 150, 4780.Google Scholar
Park, YW, Kim, Y, Lee, JH (2012). Antipsychotic-induced sexual dysfunction and its management. World J Mens Health, 30(3), 153159.Google Scholar
Perdigues, SR, Quecuti, RS, Mane, A, et al. (2016). An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol, 26(1), 156161.Google Scholar
Pfuhlmann, B, Hiemke, C, Unterecker, S, et al. (2009). Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol, 29(4), 392394.Google Scholar
Polcwiartek, C, Nielsen, J (2016). The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology, 233(5), 741750.Google Scholar
Potkin, SG, Basile, VS, Jin, Y, et al. (2003). D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry, 8, 109113.Google Scholar
Regen, F, Herzog, I, Hahn, E, et al. (2017). Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol, 316, 1016.Google Scholar
Remington, G, Lee, J, Agid, O, et al. (2016). Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf, 15(9), 11931203.Google Scholar
Roberts, CE, Mortenson, LY, Merrill, DB, et al. (2011). Successful rechallenge with clozapine after eosinophilia. Am J Psychiatry, 168(11), 11471151.Google Scholar
Rogers, DP, Shramko, JK (2000). Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy, 20(9), 10921095.Google Scholar
Ronaldson, KJ, Taylor, AJ, Fitzgerald, PB, et al. (2010). Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry, 71(8), 976981.Google Scholar
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2012). Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res, 141(2–3), 173178.Google Scholar
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 24(1), 7078.Google Scholar
Roth, BL, Driscol, J (2013). PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 10.10.13 from ‘Archived copy’. Archived from the original on 8.11.13. Retrieved 25.11.13.Google Scholar
Samara, MT, Dold, M, Gianatsi, M, et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73(3), 199210.Google Scholar
Seeman, P (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci, 5, 2429.Google Scholar
Selent, J, Lopez, L, Sanz, F, Pastor, M (2008). Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new β2 adrenergic receptor template. ChemMedChem, 3, 11941198.Google Scholar
Shirazi, A, Stubbs, B, Gomez, L, et al. (2016). Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci, 17(6), 863.Google Scholar
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine v. first- and second-generation antipsychotics in treatment refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 209(5), 385392.Google Scholar
Siskind, D, Siskind, V, Kisely, S (2017). Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry, 62(11), 772777.Google Scholar
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S (2012). Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull, 38(5), 10031011.Google Scholar
Sommer, IE, van Westrhenen, R, Begemann, MJH, et al. (2014). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull, 40(1), 181191.Google Scholar
Stoecker, ZR, George, WT, O’Brien, JB, et al. (2017). Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol, 32(3), 155160.Google Scholar
Suppes, T, Webb, A, Paul, B, et al. (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry, 156, 11641169.Google Scholar
Suzuki, T, Remington, G, Uchida, H, et al. (2011a). Mangement of schizophrenia in late life with antipsychotic medications. A qualitative review. Drugs Aging, 28(12), 961980.Google Scholar
Suzuki, T, Uchida, H, Watanabe, K, Kashima, H (2011b). Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull, 44(1), 3260.Google Scholar
Tanahashi, S, Yamamura, S, Nakagawa, M, Motomura, E, Okada, M (2012). Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol, 165(5), 15431555.Google Scholar
Testani, M Jr (1994). Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry, 55(11), 497498.Google Scholar
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 374(9690), 620627.Google Scholar
Tiihonen, J, Haukka, J, Taylor, M, et al. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry, 168(6), 603609.Google Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686693.Google Scholar
Veerman, SR, Schulte, PF, Begemann, MJ, de Haan, L (2014). Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry, 47(7), 231–8.Google Scholar
World Health Organization (WHO) (2017). WHO Model Lists of Essential Medicines, 20th list, 24.1. Geneva: World Health Organization. Available at: www.who.int/medicines/publications/essentialmedicines/en/ (last accessed 9.8.17).Google Scholar
Wu, CS, Wang, SC, Gau, SSF, Tsai, HJ, Cheng, YC (2013). Association of stroke with the receptor-binding profiles of antipsychotics – a case-crossover study. Biol Psychiatry, 73, 414421.Google Scholar
Wu, CS, Tsai, YT, Tsai, HJ (2015). Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc, 4(2), e001568.Google Scholar
Wu, Y, Blichowski, M, Daskalakis, ZJ, et al. (2011). Evidence that clozapine directly interacts on the GABAB receptor. Neuroreport, 22(13), 637641.Google Scholar
Xiang, YQ, Zhang, ZJ, Weng, YZ, et al. (2006). Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res, 83(2–3), 201210.Google Scholar
Yang, SY, Liao, YT, Liu, HC, et al. (2013). Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psychiatry, 74, e79e86.Google Scholar
Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res, 250, 6570.Google Scholar
Yusufi, B, Mukherjee, S, Flanagan, R, et al. (2007). Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int J Psychopharmacol, 22, 238243.Google Scholar
Zheng, W, Xiang, YT, Yang, XH, Xiang, YQ, de Leon, J (2017). Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry, 78(5), e498e505.Google Scholar

References

Abou-Saleh, MT, Müller-Oerlinghausen, B, Coppen, AJ (2017). Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J Bipolar Disord, 5, 11.Google Scholar
Ahrens, B, Müller-Oerlinghausen, B (2001). Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry, 34(4), 132136.Google Scholar
Aubrey, RE, Scott, L, Cassidy, E (2017). Lithium monitoring patterns in the United Kingdom and Ireland: can shared care agreements play a role in monitoring quality? A systematic review. Ir J Psychol Med, 34, 127140.Google Scholar
Baird-Gunning, J, Lea-Henry, T, Hoegberg, LCG, Gosselin, S, Roberts, DM (2017). Lithium poisoning. J Intensive Care Med, 32, 249263.Google Scholar
Barker, WA, Scott, J, Eccleston, D (1987). The Newcastle chronic depression study: results of a treatment regime. Int Clin Psychopharmacol, 2(3), 261272.Google Scholar
Bauer, M, Gitlin, M (2016). The Essential Guide to Lithium Treatment. Berlin: Springer International Publishing AG.Google Scholar
Bauer, M, Dell’osso, L, Kasper, S, et al. (2013). Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord, 151, 209219.Google Scholar
Bell, AJ, Cole, A, Eccleston, D, Ferrier, IN (1993). Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry, 162, 689692.Google Scholar
Beurel, E, Jope, RS (2006). The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol, 79(4), 173189.Google Scholar
Beurel, E, Grieco, SF, Jope, RS (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther, 148, 114131.Google Scholar
BNF (2017). British National Formulary. London: NICE.Google Scholar
Brunello, N, Tascedda, F (2003). Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol, 6, 181189.Google Scholar
Cade, JF (1949). Lithium salts in the treatment of psychotic excitement. Med J Aust, 2, 349352.Google Scholar
Can, A, Schulze, TG, Gould, TD (2014). Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav, 123, 316.Google Scholar
Cipriani, A, Smith, K, Burgess, S, et al. (2006). Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev, (4), CD003492.Google Scholar
Cipriani, A, Barbui, C, Salanti, G, et al. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378, 13061315.Google Scholar
Cipriani, A, Hawton, K, Stockton, S, Geddes, JR (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646.Google Scholar
Cleare, A, Pariante, CM, Young, AH, et al. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol, 29, 459525.Google Scholar
Cogen, PH, Whybrow, PC (2006). Lithium: a fascinating element in neuropsychiatry. In Bauer, M, Grof, P, Muller-Oerlinghausen, B, eds., Lithium in Psychiatry: The Comprehensive Guide. London: Informa Healthcare.Google Scholar
Ferrie, L, Young, AH, McQuade, R (2005). Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. J Psychopharmacol, 19(3), 229234.Google Scholar
Franks, M, Macritchie, KA, Mahmood, T, Young, AH (2008). Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol, 22(4), 452456. doi:10.1177/0269881107085238.Google Scholar
Gershon, S, Chengappa, KN, Malhi, GS (2009). Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord, 11(Suppl 2), 3444.Google Scholar
Ghasemi, M, Dehpour, AR (2011). The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci, 32, 420434.Google Scholar
Goodwin, GM (1994). Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry, 164(2), 149152.Google Scholar
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30, 495553.Google Scholar
Grandjean, EM, Aubry, JM (2009). Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs, 23, 331349.Google Scholar
Hajek, T, Cullis, J, Novak, T, et al. (2012). Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord, 14, 261270.Google Scholar
Hajek, T, Bauer, M, Simhandl, C, et al. (2014). Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med, 44, 507517.Google Scholar
Hanson, ND, Nemeroff, CB, Owens, MJ (2011). Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. J Pharmacol Exp Ther, 337, 180186.Google Scholar
Hayes, JF, Marston, L, Walters, K, et al. (2016a). Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry, 15, 5358.Google Scholar
Hayes, JF, Pitman, A, Marston, L, et al. (2016b). Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study. JAMA Psychiatry, 73(6), 630637. doi:10.1001/jamapsychiatry.2016.0432.Google Scholar
Jope, RS, Nemeroff, CB (2016). Lithium to the rescue. Cerebrum, 2016, cer-02-16.Google Scholar
Kessing, LV, Sondergard, L, Forman, JL, Andersen, PK (2008). Lithium treatment and risk of dementia. Arch Gen Psychiatry, 65, 13311335.Google Scholar
Kessing, LV, Forman, JL, Andersen, PK (2010). Does lithium protect against dementia? Bipolar Disord, 12, 8794.Google Scholar
Kessing, LV, Vradi, E, Andersen, PK (2014). Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry, 205(3), 214220. doi:10.1192/bjp.bp.113.142802.Google Scholar
Machado-Vieira, R, Gattaz, WF, Zanetti, MV, et al. (2015). A longitudinal (6-week) 3T (1)H-MRS study on the effects of lithium treatment on anterior cingulate cortex metabolites in bipolar depression. Eur Neuropsychopharmacol, 25, 23112317.Google Scholar
Malhi, GS, Outhred, T (2016). Therapeutic mechanisms of lithium in bipolar disorder: recent advances and current understanding. CNS Drugs, 30, 931949.Google Scholar
Malhi, GS, Adams, D, Berk, M (2009). Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry, 43, 10961104.Google Scholar
Malhi, GS, Tanious, M, Das, P, Coulston, CM, Berk, M (2013). Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs, 27(2), 135153. doi:10.1007/s40263-013-0039-0.Google Scholar
Malhi, GS, Gessler, D, Outhred, T (2017). The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord, 217, 266280.Google Scholar
Mander, AJ, Loudon, JB (1988). Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet, 2(8601), 1517.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014). Bipolar disorder: assessment and management. Clinical Guidelines [CG185]. London: National Institute for Health and Care Excellence.Google Scholar
Nolen, WA, Licht, RW, Young, AH, et al.; Task Force on the treatment with lithium (2019). What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord, 21(5), 394409. doi:10.1111/bdi.12805.Google Scholar
Severus, E, Bauer, M, Geddes, J (2018). Efficacy and effectiveness of lithium in the long-term treatment of bipolar disorders: an update 2018. Pharmacopsychiatry, 51(5), 173176. doi:10.1055/a-0627-7489.Google Scholar
Shelley, R (2004). Affective disorders: 2. Lithium and anticonvulsants. In King, DJ, ed., Seminars in Psychopharmacology, 2nd ed. London: Royal College of Psychiatrists.Google Scholar
Song, J, Sjölander, A, Joas, E, et al. (1917). Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry, 174(8), 795802. doi:10.1176/appi.ajp.2017.16050542.Google Scholar
Taylor, D, Paton, C, Kapur, S (2015). The Maudsley Prescribing Guidelines in Psychiatry, 12th ed. Hoboken: Wiley Blackwell.Google Scholar
Tiihonen, J, Tanskanen, A, Hoti, F, et al. (2017). Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry, 4(7), 547553. doi:10.1016/S2215-0366(17)30134-7.Google Scholar
Viguera, AC, Nonacs, R, Cohen, LS, et al. (2000). Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry, 157, 179184.Google Scholar
Wakita, M, Nagami, H, Takase, Y, et al. (2015). Modifications of excitatory and inhibitory transmission in rat hippocampal pyramidal neurons by acute lithium treatment. Brain Res Bull, 117, 3944.Google Scholar
Weeks, ME, Larson, ME (1937). J.A. Arfwedson and his services to chemistry. J Chem Educ, 14, 403407.Google Scholar
Weisler, RH, Nolen, WA, Neijber, A, Hellqvist, A, Paulsson, B; Trial 144 Study Investigators (2011). Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry, 72(11), 14521464. doi:10.4088/JCP.11m06878. Erratum in: J Clin Psychiatry 2014, 75(3), 290.Google Scholar
World Health Organization (2000). Preventing Suicide: A Resource for General Physicians. Available at: www.who.int/mental_health/media/en/56.pdf (last accessed 22.8.19).Google Scholar
Young, AH (2014). Lithium and suicide. Lancet Psychiatry, 1(6), 483484. doi:10.1016/S2215-0366(14)70320-7.Google Scholar

References

Acharya, S, Bussel, JB (2000). Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol, 22(1), 6265.Google Scholar
Aiken, CB, Orr, C (2010). Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry, 7, 2732.Google Scholar
Aliyev, NA, Aliyev, ZN (2008). Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry, 23, 109114.Google Scholar
Allen, MH, Hirschfeld, RM, Wozniak, PJ, Baker, JD, Bowden, CL (2006). Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry, 163, 272275.Google Scholar
Angus-Lepan, H, Liu, R (2018). Weighing the risks of valproate in women who could become pregnant. BMJ, 361, k1596.Google Scholar
Azorin, JM, Bowden, CL, Garay, RP, et al. (2010). Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatr Dis Treat, 6, 3746.Google Scholar
Ballenger, JC, Post, RM (1978). Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol, 2, 159175.Google Scholar
Ballenger, JC, Post, RM (1980). Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry, 137, 782–790.Google Scholar
Belcastro, V, D’Egidio, C, Striano, P, Verrotti, A (2013). Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res, 107, 18.Google Scholar
Bjerkedal, T, Czeizel, A, Goujard, J, et al. (1982). Valproic acid and spina bifida. Lancet, 2, 1096.Google Scholar
BNF (2019). British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Available at: www.medicinescomplete.com (last accessed 13.8.19).Google Scholar
Bond, DJ, Lam, RW, Yatham, LN (2010). Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord, 124, 228234.Google Scholar
Bowden, CL, Asnis, GM, Ginsberg, LD, et al. (2004). Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf, 27, 173184.Google Scholar
Brodie, MJ (1992). Lamotrigine. Lancet, 339, 13971400.Google Scholar
Brodie, MJ (2010). Antiepileptic drug therapy the story so far. Seizure, 19, 650655.Google Scholar
Brodie, MJ, Mintzer, S, Pack, AM, et al. (2013). Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia, 54, 1127.Google Scholar
Bromley, R, Weston, J, Adab, N, et al. (2014). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev, (10), CD010236.Google Scholar
Campbell, E, Kennedy, F, Russell, A, et al. (2014). Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry, 85, 10291034.Google Scholar
Carrigan, PJ, Brinker, DR, Cavanaugh, JH, Lamm, JE, Cloyd, JC (1990). Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). J Clin Pharmacol, 30, 743747.Google Scholar
Chen, PS, Peng, GS, Li, G, et al. (2006). Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry, 11, 11161125.Google Scholar
Christensen, J, Gronborg, TK, Sorensen, MJ, et al. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309, 16961703.Google Scholar
Chung, S, Wang, N, Hank, N (2007). Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure, 16, 296304.Google Scholar
Cipriani, A, Barbui, C, Salanti, G, et al. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378, 13061315.Google Scholar
Citrome, L, Volavka, J (2011). Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs, 25, 10091021.Google Scholar
Cleare, A, Pariante, CM, Young, AH, et al.; Members of the Consensus Meeting (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol, 29, 459525.Google Scholar
Cohen, AF, Land, GS, Breimer, DD, et al. (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther, 42, 535541.Google Scholar
Cohen, MJ, Meador, KJ, Browning, N, et al. (2011). Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav, 22, 240246.Google Scholar
Cohen, MJ, Meador, KJ, Browning, N, et al.; NEAD study group (2013). Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav, 29, 308315.Google Scholar
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry, 74, 675684.Google Scholar
Crawford, MJ, Sanatinia, R, Barrett, B, et al. (2018). Lamotrigine for people with borderline personality disorder: a RCT. Health Technol Assess, 22, 168.Google Scholar
Cummings, C, Stewart, M, Stevenson, M, Morrow, J, Nelson, J (2011). Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child, 96, 643647.Google Scholar
Davis, LL, Ryan, W, Adinoff, B, Petty, F (2000). Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol, 20, 1S17S.Google Scholar
Dias, VV, Balanza-Martinez, V, Soeiro-de-Souza, MG, et al. (2012). Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand, 126, 315331.Google Scholar
Drevets, WC (2000). Neuroimaging studies of mood disorders. Biol Psychiatry, 48, 813829.Google Scholar
Drugbank (2019a). Lamotrigine. Available at: www.drugbank.ca/drugs/DB00555 (last accessed 6.8.19).Google Scholar
Drugbank (2019b). Carbamazepine. Available at: www.drugbank.ca/drugs/DB00564 (last accessed 6.8.19).Google Scholar
electronic Medicines Compendium (2019a). Summary of Product Characteristics: Depakote. SANOFI. Available at: www.medicines.org.uk/emc/product/6113/smpc (last accessed 6.8.19).Google Scholar
electronic Medicines Compendium (2019b). Summary of Product Characteristics: Lamotrigine. Accord Healthcare Limited. Available at: www.medicines.org.uk/emc/product/6091/smpc (last accessed 6.8.19).Google Scholar
electronic Medicines Compendium (2019c). Summary of Product Characteristics: Carbamazepine. Novartis Pharmaceuticals UK Ltd. Available at: www.medicines.org.uk/emc/product/1040/smpc (last accessed 6.8.19).Google Scholar
Elkjaer, LS, Bech, BH, Sun, Y, Laursen, TM, Christensen, J (2018). Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurol, 19, 19.Google Scholar
European Medicines Agency (2018). New measures to avoid valproate exposure in pregnancy endorsed. Press release, 23 March 2018. Available at: www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/03/WC500246391.pdf (last accessed 22.8.19).Google Scholar
Fleming, J, Chetty, M (2005). Psychotropic drug interactions with valproate. Clin Neuropharmacol, 28, 96101.Google Scholar
Franks, M, Macritchie, KA, Mahmood, T, Young, AH (2008). Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol, 22, 452456.Google Scholar
Frye, MA, Ketter, TA, Kimbrell, TA, et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol, 20, 607614.Google Scholar
Geddes, JR, Calabrese, JR, Goodwin, GM (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry, 194, 49.Google Scholar
Geddes, JR, Gardiner, A, Rendell, J, et al.; CEQUEL Investigators and Collaborators (2016). Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry, 3, 3139.Google Scholar
Ghabrash, MF, Comai, S, Tabaka, J, et al. (2016). Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. World J Biol Psychiatry, 17, 165170.Google Scholar
Ghodke-Puranik, Y, Thorn, CF, Lamba, JK, et al. (2013). Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics, 23, 236241.Google Scholar
Goodwin, GM, Bowden, CL, Calabrese, JR, et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry, 65, 432441.